Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Tzu

Ophthalmology Houston, TX Medical Doctor

NPI 1962630335 CMS profile 316511

2727 Gramercy St, Suite 200, Houston, TX 77025

Open in the dashboard

General payments

$21,931

122 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$43,852

6 holdings reported · through program year 2025

Through program year 2025, Jonathan Tzu of Houston, TX is reported in the CMS Open Payments database as having received $21,931 across 122 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $43,852 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,539 16
2024 General $5,950 23
2023 General $1,031 25
2022 General $4,548 17
2021 General $1,530 13
2020 General $483 5
2019 General $5,849 23
2024 Ownership $11,926 1
2023 Ownership $11,926 1
2022 Ownership $5,000 1
2021 Ownership $5,000 1
2020 Ownership $5,000 1
2019 Ownership $5,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Tzu
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Jonathan Tzu were reported at $2,539. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Jonathan Tzu Ophthalmology median Middle half National median
2019 $5,849 $258 $104–$655 $163
2020 $483 $126 $45–$321 $114
2021 $1,530 $205 $76–$534 $132
2022 $4,548 $266 $100–$678 $149
2023 $1,031 $308 $117–$745 $160
2024 $5,950 $340 $127–$846 $164
2025 $2,539 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $7,557 13 payments
  2. Genentech USA, Inc. $5,445 32 payments
  3. Genentech, Inc. $2,372 4 payments
  4. US Retina LLC $2,185 6 payments
  5. Coherus Biosciences Inc. $1,122 2 payments
  6. Regeneron Healthcare Solutions, Inc. $1,014 26 payments
  7. Allergan Inc. $557 11 payments
  8. Regeneron Pharmaceuticals, Inc. $320 3 payments
  9. Bausch & Lomb, a division of Bausch Health US, LLC $313 4 payments
  10. Apellis Pharmaceuticals, Inc. $154 4 payments
  11. Other $891 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,410 7 payments
  2. Food and Beverage $5,527 106 payments
  3. Current or prospective ownership or investment interest $2,185 6 payments
  4. Travel and Lodging $809 3 payments
Products named General payments · program years 2019–2025
  1. Izervay $7,462 10 payments
  2. Lucentis $4,370 6 payments
  3. VABYSMO $2,821 27 payments
  4. Cimerli $1,122 2 payments
  5. EYLEA $986 17 payments
  6. Non-Covered Product $489 2 payments
  7. EYLEA HD $348 12 payments
  8. OZURDEX $338 7 payments
  9. STELLARIS $241 3 payments
  10. STELLARIS PC $176 2 payments
  11. Other $904 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

516

Median for Ophthalmology: 891

Drug cost

$11,777

Median for Ophthalmology: $68,233

Branded share of claims

17.6%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 143 $6,737
Ketorolac Tromethamine Generic 82 $1,850
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 79 $1,107
Latanoprost Generic 101 $849
Ofloxacin Generic 73 $803
Moxifloxacin Moxifloxacin Hcl Brand 12 $185
Brimonidine Tartrate Generic 13 $129
Timolol Maleate Generic 13 $117

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$3,174,237

Of which drugs: $2,647,968

Medicare patients

812

Average age 77

Services billed

42,807

429 women, 383 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 41%
Ischemic heart disease 36%
Chronic kidney disease 30%
Atrial fibrillation 21%
Heart failure 20%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 179 2,248 $1,477,661
Injection, faricimab-svoa, 0.1 mg J2777 Office 79 28,380 $779,987
Injection, ranibizumab, 0.1 mg J2778 Office 41 1,089 $140,195
Injection, aflibercept hd, 1 mg J0177 Office 14 496 $131,189
Injection, bevacizumab, 10 mg J9035 Office 73 407 $21,866

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Izervay
  • Astellas Pharma US Inc $5,297
$5,297 — —
VABYSMO
  • Genentech USA, Inc. $352
  • Genentech, Inc. $123
$475 — 28,380
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $137
$137 — 496
Syfovre
  • Apellis Pharmaceuticals, Inc. $34
$34 — —
EYLEA
  • Regeneron Healthcare Solutions, Inc. $7
$7 — 2,248

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record